This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
The Spectrum of Molecular Testing Protocols for HCV: Identifying and Monitoring Disease Progression and Treatment Efficacy

The Spectrum of Molecular Testing Protocols for HCV: Identifying and Monitoring Disease Progression and Treatment Efficacy

Format

Patient Case Study

Time to Complete

30 minutes

Released

August 29, 2017

Expires

August 29, 2018
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 CreditTM

Accredited Provider



Provided by Haymarket Medical Education

Commercial Supporter

Supported by an educational grant from Quest Diagnostics

Program Description

Over the last few years, a number of rapidly evolving new treatment options for chronic hepatitis C virus (HCV) infection have become available, including the emergence of new direct-acting antiviral agents (DAAs). Treatment with these DAAs—which include 3 NS3-4A protease inhibitors, 5 NS5A inhibitors, and 2 NS5B polymerase inhibitors in multiple combination regimens for the management of 6 HCV genotypes—has led to dramatic advances in terms of treatment efficacy, with sustained viral response (SVR) rates greater than 95% and minimal associated side effects. Although monitoring of clinical response and adverse events has been greatly simplified, many factors should be considered to determine the most appropriate DAA regimen, such as HCV genotype (including associated subtypes). Identifying genotype at baseline to differentiate treatment failure or re-infection has an important role. Assessment of liver fibrosis in HCV infection also is considered a relevant part of patient care and key for decision making.

Intended Audience

Gastroenterologists, hepatologists, infectious disease specialists, internists, primary care clinicians, and other healthcare providers (HCPs) who treat patients with hepatitis C

Educational Objectives

After participating in this activity, clinicians should be better able to:

  • Select the appropriate direct-acting antiviral agent (DAA) for hepatitis C virus (HCV) infection based on viral genotypes (and subtype) and associated complications
  • Identify the emergence of HCV resistance-associated variants (RAVs) following treatment with selected DAA regimens
  • Implement strategies, including the spectrum of molecular testing protocols, to identify and monitor disease progression and treatment efficacy and potentially avert HCV treatment resistance
  • Facilitate better linkage of care among specialists and other providers to strengthen screening, treatment, and monitoring practices, particularly for underserved and marginalized populations

Conflict of Interest Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.

Faculty

Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
Chicago, IL

Dr. Reau is a consultant for AbbVie Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., and Merck & Co. She receives research funds from AbbVie Inc., Genfit SA, Shire, and TARGET PharmaSolutions.

Accredited Provider Disclosure

Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Haymarket Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education and Quest Diagnostics. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the CME certification of this activity, please contact HME at cmequestions@haymarketmedical.com.

If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue